Breastcancer.org Podcast
Verzenio Improves Overall Survival in Hormone Receptor-Positive, HER2-Negative, Advanced Stage Breast Cancer
28 Sep 2022
At the European Society for Medical Oncology Congress 2022, Dr. Matthew Goetz presented interim overall survival results from the MONARCH 3 study showing that adding Verzenio to an aromatase inhibitor improves overall survival by 12.6 months for advanced-stage, hormone receptor-positive, HER2-negative breast cancer. Listen to the podcast to hear Dr. Goetz explain: how Verzenio works the aims of MONARCH 3 study the difference between progression-free and overall survival and why each is important Verzenio side effects what the results mean for people diagnosed with advanced-stage, hormone receptor-positive, HER2-negative breast cancer
No persons identified in this episode.
This episode hasn't been transcribed yet
Help us prioritize this episode for transcription by upvoting it.
Popular episodes get transcribed faster
Other recent transcribed episodes
Transcribed and ready to explore now
3ª PARTE | 17 DIC 2025 | EL PARTIDAZO DE COPE
01 Jan 1970
El Partidazo de COPE
13:00H | 21 DIC 2025 | Fin de Semana
01 Jan 1970
Fin de Semana
12:00H | 21 DIC 2025 | Fin de Semana
01 Jan 1970
Fin de Semana
10:00H | 21 DIC 2025 | Fin de Semana
01 Jan 1970
Fin de Semana
13:00H | 20 DIC 2025 | Fin de Semana
01 Jan 1970
Fin de Semana
12:00H | 20 DIC 2025 | Fin de Semana
01 Jan 1970
Fin de Semana